Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC.
作者信息
Ismail R K, Schramel F M N H, van Dartel M, Pasmooij A M G, der Welle C M Cramer-van, Hilarius D L, de Boer A, Wouters M W J M, van de Garde E M W
机构信息
Dutch Institute for Clinical Auditing, Leiden, the Netherlands.
Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
出版信息
BMC Med Res Methodol. 2023 Jan 27;23(1):26. doi: 10.1186/s12874-023-01850-7.
Abstract
摘要
Zotero 插件